Oyster Point Pharma, Inc. Banner Image

Oyster Point Pharma, Inc. has reached its limit for free report views

Work for Oyster Point Pharma, Inc.? Upgrade Your Profile and unlock all your annual reports.

Oyster Point Pharma, Inc.

  • Ticker OYST
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Oyster Point Pharma, Inc. Logo Image
  • 11-50 Employees
  • Based in Princeton, New Jersey
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye diseaseMore. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit (LFU).
Oyster Point Pharma, Inc.

Most Recent Annual Report

Oyster Point Pharma, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Oyster Point Pharma, Inc. has reached its limit for free report views.